WHY IT MATTERS: Pregnant individuals using cannabis for nausea, anxiety, or pain should know that emerging placental research suggests potential long-term psychiatric risks to their child that current safety guidelines may still be underestimating. CLINICAL OVERVIEW: Emerging research suggests that prenatal cannabis exposure may leave measurable biological signatures in placental tissue that are associated with increased schizophrenia risk in offspring. The placenta acts as a dynamic interface between maternal and fetal environments, and cannabinoids can cross this barrier and influence fetal neurodevelopment during critical windows of brain formation.
Placental Changes From Prenatal Cannabis Exposure Could Flag Higher Schizophrenia …
WHY IT MATTERS: Pregnant patients who have used cannabis, even early in pregnancy, may want to discuss this emerging research with their obstetric and psychiatric care teams when considering their child’s long-term neurodevelopmental monitoring. CLINICAL OVERVIEW: Emerging research suggests that prenatal cannabis exposure may produce measurable epigenetic and gene expression changes in placental tissue, particularly in pathways associated with neurodevelopmental risk including schizophrenia. The placenta, long underappreciated as a window into fetal programming, appears to reflect cannabis-related disruptions that could correlate with altered brain development trajectories in offspring.